Item 7.01. Regulation FD Disclosure.

BeiGene, Ltd. ("BeiGene") expects to announce its financial results for the three and nine months ended September 30, 2021 on Thursday, November 4, 2021 after the close of U.S. financial markets.

Item 8.01. Other Events.

On October 20, 2021, BeiGene and Nanolek, a biopharmaceutical company specializing in the production of import-substituting and innovative drugs in Russia, announced that BRUKINSA® (zanubrutinib) has received approval from the Russia Ministry of Health for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. BeiGene and Nanolek entered into an exclusive distribution agreement for Nanolek to commercialize BRUKINSA in the Russian Federation. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "BeiGene and Nanolek Announce Approval in Russia for
                          BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or
                          Refractory Mantle Cell Lymphoma", issued by BeiGene, Ltd. on October 20,
                          2021.

       104                The cover page from this Current Report on Form 8-K, formatted in Inline
                          XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses